Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Not Available
Phase III
Adults
Not Available
Not Available
Moses, Kelvin
International
Vanderbilt University
05-01-2019
Treatment
VICCURO17115
NCT03395197

Eligibility

18 Years
MALE
NO
Inclusion Criteria:

Inclusion Criteria: Histologically or cytologically confirmed adenocarcinoma of the prostate withoutsmall cell or signet cell features Asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be 1.5 times the upper limit of normal (ULN) (>3 × ULN for patients with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation). - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times ULN (>5 × ULN if liver function abnormalities are due to hepatic metastasis). - Albumin

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: